Prevalence and Risk Factors of Sleep Disordered Breathing in Fabry disease: A Prospective Cohort Study

Daniel Franzen, Nicolas Gerard, Daniel J Bratton, Annette Wons, Thomas Gaisl, Noriane A Sievi, Christian F Clarenbach, Malcolm Kohler, Pierre A Krayenbühl, Daniel Franzen, Nicolas Gerard, Daniel J Bratton, Annette Wons, Thomas Gaisl, Noriane A Sievi, Christian F Clarenbach, Malcolm Kohler, Pierre A Krayenbühl

Abstract

Excessive daytime sleepiness (EDS) is a frequently reported and not well-understood symptom in patients with Fabry disease (FD). Sleep-disordered breathing (SDB) is a possible factor. As deposition of glycosphingolipids in the upper airway muscles is likely, we hypothesized that obstructive sleep apnoea (OSA) is highly prevalent in FD and positively associated with its severity.All patients with FD who are followed in the Fabry cohort of the University Hospital Zurich (n = 62) were asked to participate in this prospective cohort study. Eligible patients were prospectively investigated by assessing their daytime sleepiness using the Epworth Sleepiness Scale (ESS), the severity of FD using the Mainz Severity Score Index (MSSI), and by an ambulatory overnight respiratory polygraphy between November 1, 2013, and January 31, 2015. SDB was defined as an apnea/hypopnea index (AHI) of > 5/h.Fifty-two patients (mean ± SD age 42.8 ± 14.7 years, 33% men, mean ± SD BMI 23.4 ± 3.6 kg/m) with a median (IQR) MSSI of 12 (5-19) were included. Median (IQR) ESS was 6 (2-10) and 7 patients (14%) had an ESS > 10. Thirteen patients (25%) had SDB (78% obstructive sleep apnea, 22% central sleep apnea). In the multivariable analysis, the age was the only statistically significant predictor of SDB (OR 1.11, 95% CI 1.04-1.18, P = 0.001). ESS was associated with depression (P < 0.001) but not AHI nor age.This study shows that SDB, especially obstructive sleep apnea is highly prevalent in patients with Fabry disease. However, EDS in FD seems to be related with depression rather than SDB.ClinicalTrials.gov (identifier: NCT01947634).

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Study flowchart. ESS = Epworth sleepiness scale; MSSI = Mainz Severity Score Index; PHQ-9 = patient health questionnaire.
FIGURE 2
FIGURE 2
Prevalence of sleep-disordered breathing in the Fabry cohort (n = 52). AHI  = apnea/hypopnea index.

References

    1. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372:1427–1435.
    1. Duning T, Deppe M, Keller S, et al. Excessive daytime sleepiness is a common symptom in Fabry disease. Case Rep Neurol 2009; 1:33–40.
    1. Pallesen S, Nordhus IH, Omvik S, et al. Prevalence and risk factors of subjective sleepiness in the general adult population. Sleep 2007; 30:619–624.
    1. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338–346.
    1. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012; 8:597–619.
    1. Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest 2000; 118:372–379.
    1. Duning T, Deppe M, Brand E, et al. Brainstem involvement as a cause of central sleep apnea: pattern of microstructural cerebral damage in patients with cerebral microangiopathy. PLoS One 2013; 8:e60304.
    1. Robbins J, Redline S, Ervin A, et al. Associations of sleep-disordered breathing and cerebral changes on MRI. J Clin Sleep Med 2005; 1:159–165.
    1. Ding J, Nieto FJ, Beauchamp NJ, Jr, et al. Sleep-disordered breathing and white matter disease in the brainstem in older adults. Sleep 2004; 27:474–479.
    1. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50:1746–1749.
    1. Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 2006; 5:791–795.
    1. Nigro CA, Dibur E, Malnis S, et al. Validation of ApneaLink Ox for the diagnosis of obstructive sleep apnea. Sleep Breath 2013; 17:259–266.
    1. Chen H, Lowe AA, Bai Y, et al. Evaluation of a portable recording device (ApneaLink) for case selection of obstructive sleep apnea. Sleep Breath 2009; 13:213–219.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540–545.
    1. Bloch KE, Schoch OD, Zhang JN, et al. German version of the Epworth Sleepiness Scale. Respiration 1999; 66:440–447.
    1. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004; 65:299–307.
    1. Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ 2012; 184:E191–196.
    1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230–1235.
    1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165:1217–1239.
    1. Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163:608–613.
    1. Lévy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers 2015; 15024 (doi:10.1038/nrdp.2015.24).
    1. Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177:1006–1014.
    1. Chen HL, Lu CH, Lin HC, et al. White matter damage and systemic inflammation in obstructive sleep apnea. Sleep 2015; 38:361–370.
    1. Macey PM, Kumar R, Woo MA, et al. Brain structural changes in obstructive sleep apnea. Sleep 2008; 31:967–977.
    1. Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci 2011; 305:41–44.
    1. Lee W, Lee SA, Chung YS, et al. The relation between apnea and depressive symptoms in men with severe obstructive sleep apnea: mediational effects of sleep quality. Lung 2015; 193:261–267.
    1. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291:2013–2016.
    1. Yaggi HK, Strohl KP. Adult obstructive sleep apnea/hypopnea syndrome: definitions, risk factors, and pathogenesis. Clin Chest Med 2010; 31:179–186.
    1. Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417:449–455.
    1. Franzen D, Krayenbuehl PA, Lidove O, et al. Pulmonary involvement in Fabry disease: overview and perspectives. Eur J Intern Med 2013; 24:707–713.
    1. Aboussouan LS. Sleep-disordered breathing in neuromuscular disease. Am J Respir Crit Care Med 2015; 191:979–989.
    1. Lyons OD, Chan CT, Elias RM, et al. Relationship of left atrial size to obstructive sleep apnea severity in end-stage renal disease. Sleep Med 2014; 15:1314–1318.
    1. Calvin AD, Somers VK, Johnson BD, et al. Left atrial size, chemosensitivity, and central sleep apnea in heart failure. Chest 2014; 146:96–103.
    1. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7:677–685.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera